share_log

Arcutis Biotherapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Topper David Joseph

Arcutis Biotherapeutics | 4: Statement of changes in beneficial ownership of securities

Arcutis Biotherapeutics | 4：持股变动声明
SEC announcement ·  04/11 20:36
Moomoo AI 已提取核心信息
David Joseph Topper, the Chief Financial Officer of Arcutis Biotherapeutics, has been granted 110,000 shares of common stock on April 10, 2024. The transaction, which was completed on the same day, was a grant with a transaction price of $0.00 per share, indicating that the shares were likely awarded as part of compensation or a similar incentive plan. Following this transaction, Topper directly owns a total of 110,000 shares in the company. The grant of shares to a high-level executive is a common practice in the industry and reflects the company's commitment to aligning the interests of its executives with those of its shareholders.
David Joseph Topper, the Chief Financial Officer of Arcutis Biotherapeutics, has been granted 110,000 shares of common stock on April 10, 2024. The transaction, which was completed on the same day, was a grant with a transaction price of $0.00 per share, indicating that the shares were likely awarded as part of compensation or a similar incentive plan. Following this transaction, Topper directly owns a total of 110,000 shares in the company. The grant of shares to a high-level executive is a common practice in the industry and reflects the company's commitment to aligning the interests of its executives with those of its shareholders.
Arcutis Biotherapeutics首席财务官大卫·约瑟夫·托珀已于2024年4月10日获得11万股普通股。该交易于当天完成，是一笔赠款，交易价格为每股0.00美元，这表明这些股票可能是作为薪酬或类似激励计划的一部分授予的。在这笔交易之后，Topper直接拥有该公司共计110,000股股份。向高级管理人员授予股份是业内普遍的做法，反映了公司致力于协调高管利益与股东利益的承诺。
Arcutis Biotherapeutics首席财务官大卫·约瑟夫·托珀已于2024年4月10日获得11万股普通股。该交易于当天完成，是一笔赠款，交易价格为每股0.00美元，这表明这些股票可能是作为薪酬或类似激励计划的一部分授予的。在这笔交易之后，Topper直接拥有该公司共计110,000股股份。向高级管理人员授予股份是业内普遍的做法，反映了公司致力于协调高管利益与股东利益的承诺。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息